RDY
DR REDDYS LABORATORIES LTDPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 24 Trial readout: Results Pending: Beclomethasone Dipropionate (Phase 3), Co…
- Mar 16 Trial readout: T-90d Trial Readout: BL-B01D1 (Phase 3)
- Mar 16 Trial readout: T-90d Trial Readout: Domvanalimab (Phase 3)
- Mar 16 Trial readout: T-90d Trial Readout: Ivaltinostat (Phase 2)
- Mar 19 Trial readout: Results Pending: IBI310 (Phase 3), Completed 78d ago
- Sep 29 ▲ Citigroup upgrades
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 21 added (1 new), 29 trimmed or exited.
- AnalystsBULLISH
26 of 42 rate it Buy or better.
- Short sellersSTEADY
Short interest −3.2% to 25.30M shares. 7.8 days to cover, ≈3.0% of shares.
- TrendUPTREND
12% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 26.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | DOUBLED | $306.6M |
| Robeco Institutional Asset Management B.V. | TRIM | $109.6M |
| FRANKLIN TEMPLETON INC | DOUBLED | $94.5M |
| UBS Group AG | TRIM | $14.4M |
| Grantham, Mayo, Van Otterloo & Co. LLC | DOUBLED | $7.7M |
| CITIGROUP INC | DOUBLED | $6.4M |
| Jump Financial, LLC | DOUBLED | $4.9M |
| MARSHALL WACE, LLP | NEAR_EXIT | $3.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
42 analysts| Date | Firm | Rating |
|---|---|---|
| Sep 29, 2026 | Citigroup UPGRADE | Buy |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026Washington
SecBot reports
73 filings · 7 bullish · 7 bearish · 1 mixed · 58 neutral- BULLISH 6-KNov 16, 2026
Dr. Reddy's Laboratories filed a Form 6-K reporting that the USFDA classified the GMP inspection at its Bachupally FTO-3 facility as Voluntary Action Indicated (VAI) and closed the inspection. This is a positive regulatory outcome, removing a potential overhang for the facility.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 6-KNov 10, 2026
Dr. Reddy's filed a Form 6-K to announce that management will participate in investor conferences…
Routine scheduling notice with no new information. Monitor for any material disclosures that may arise from the investor meetings.
- NEUTRAL INST-CLUSTERNov 9, 2026
Institutional activity in RDY was mixed during Q3 2026, with 6 small buyers (net +$6.4M) and 6…
The large trim by Robeco, the top 13F holder, warrants monitoring for further selling or a thesis change. With no insider buying, the cluster lacks corroboration; watch next quarter's 13F for…
- NEUTRAL 6-KNov 5, 2026
Dr. Reddy's announced that Brazil's ANVISA has granted marketing authorization for its generic…
Monitor Dr. Reddy's for launch timing and initial market share in Brazil's semaglutide market, as well as potential regulatory approvals in other Latin American markets. The approval is incremental…
All RDY filing & press-release reports (73)
- 6-K reportNov 16, 2026
- 6-K reportNov 10, 2026
- INST-CLUSTER reportNov 9, 2026
- 6-K reportNov 5, 2026
- 6-K reportNov 4, 2026
- 144 reportNov 2, 2026
- 6-K reportOct 29, 2026
- 6-K reportOct 28, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 23, 2026
- 6-K reportOct 23, 2026
- 6-K reportOct 23, 2026
- 6-K reportOct 23, 2026
- 6-K reportOct 21, 2026
- 6-K reportOct 14, 2026
- 6-K reportOct 8, 2026
- 6-K reportOct 7, 2026
- 6-K reportOct 5, 2026
- 6-K reportSep 22, 2026
- 6-K reportSep 21, 2026
- 6-K reportSep 18, 2026
- 6-K reportSep 14, 2026
- 6-K reportSep 10, 2026
- 6-K reportSep 10, 2026
- 6-K reportAug 26, 2026
- 6-K reportAug 17, 2026
- 6-K reportAug 13, 2026
- 6-K reportAug 10, 2026
- 6-K reportAug 3, 2026
- 6-K reportJul 29, 2026
- 6-K reportJul 23, 2026
- 6-K reportJul 23, 2026
- 6-K reportJul 23, 2026
- 6-K reportJul 23, 2026
- 6-K reportJul 22, 2026
- 6-K reportJul 22, 2026
- 6-K reportJul 22, 2026
- 6-K reportJul 15, 2026
- 6-K reportJul 13, 2026
- 6-K reportJul 10, 2026
- 6-K reportJul 9, 2026
- 6-K reportJun 22, 2026
- 6-K reportJul 1, 2026
- 6-K reportJul 1, 2026
- 6-K reportJun 30, 2026
- 6-K reportJun 30, 2026
- 6-K reportJun 30, 2026
- 6-K reportJun 26, 2026
- 6-K reportJun 15, 2026
- 6-K reportJun 10, 2026
- 6-K reportJun 5, 2026
- 6-K reportJun 3, 2026
- 6-K reportJun 1, 2026
- 6-K reportJun 1, 2026
- 20-F reportMay 29, 2026
- 6-K reportMay 28, 2026
- 6-K reportMay 28, 2026
- 6-K reportMay 18, 2026
- 6-K reportMay 18, 2026
- 6-K reportMay 15, 2026
- 6-K reportMay 12, 2026
- 6-K reportMay 12, 2026
- 6-K reportMay 12, 2026
- 6-K reportMay 12, 2026
- 6-K reportMay 11, 2026
- 6-K reportApr 29, 2026
- 6-K reportApr 24, 2026
- 6-K reportApr 24, 2026
- 6-K reportApr 16, 2026
- 6-K reportApr 8, 2026
- 6-K reportMar 26, 2026
- INST-CLUSTER reportFeb 28, 2026